Drugs that contain Fulvestrant
1. Faslodex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8329680 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
| US8466139 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
| US6774122 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
| US7456160 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
|
US8329680 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
|
US6774122 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
|
US7456160 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
|
US8466139 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-725) | Feb 19, 2019 |
| New Indication(I-749) | Aug 25, 2020 |
| New Dosing Schedule(D-126) | Sep 09, 2013 |
| M(M-103) | May 17, 2014 |
| Pediatric Exclusivity(PED) | Mar 09, 2014 |
| M(M-123) | Nov 09, 2015 |
Market Authorisation Date: 25 April, 2002
Treatment: Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy; Treatment of hr-positive, human epidermal growth factor...
Dosage: SOLUTION;INTRAMUSCULAR
How can I launch a generic of FASLODEX before it's drug patent expiration?
More Information on Dosage
FASLODEX family patents
2. Fulvestrant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833459 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(9 years from now) | |
| US10188663 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(9 years from now) | |
| US9271990 | FRESENIUS KABI USA | Fulvestrant formulations |
May, 2034
(10 years from now) | |
Market Authorisation Date: 20 May, 2019
Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women
Dosage: SOLUTION;INTRAMUSCULAR
More Information on Dosage
FULVESTRANT family patents